{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:30:14Z","timestamp":1759411814145},"reference-count":38,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.vaccine.2016.07.019","type":"journal-article","created":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T04:28:57Z","timestamp":1469075337000},"page":"4406-4414","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009\u20132010 season in the active component U.S. military and civilians aged 17\u201344years reported to the Vaccine Adverse Event Reporting System"],"prefix":"10.1016","volume":"34","author":[{"given":"Barbara H.","family":"Bardenheier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan K.","family":"Duderstadt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata J.M.","family":"Engler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.07.019_b0005","unstructured":"Centers for Disease Control and Prevention. Safety of influenza A (H1N1) 2009 monovalent vaccines \u2013 United States, October 1-November 24, 2009. MMWR Morbidity and mortality weekly report, vol. 58, 2009, pp. 1351\u20131356."},{"key":"10.1016\/j.vaccine.2016.07.019_b0010","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1016\/j.vaccine.2011.01.056","article-title":"Adverse events following pandemic influenza vaccine Pandemrix(R) reported in the French military forces\u20132009-2010","volume":"29","author":"Mayet","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.07.019_b0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/hv.7.5.14821","article-title":"Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations","volume":"7","author":"Banzhoff","year":"2011","journal-title":"Human Vaccines"},{"key":"10.1016\/j.vaccine.2016.07.019_b0020","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1016\/j.vaccine.2010.09.021","article-title":"Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010","volume":"28","author":"Vellozzi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.07.019_b0025","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1016\/j.vaccine.2013.09.066","article-title":"Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS","volume":"31","author":"Halsey","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.07.019_b0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The Vaccine Adverse Event Reporting System (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.07.019_b0035","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1016\/S0264-410X(99)00132-2","article-title":"An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system VAERS Working Group","volume":"17","author":"Singleton","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.07.019_b0040","unstructured":"Administration FaD. 21 CFR Part 600.80 Postmarketing reporting of adverse experiences. National Childhood Vaccine Injury Act of 1986 ed: Federal Register; 1997. p. (42 USC 300aa-25)."},{"key":"10.1016\/j.vaccine.2016.07.019_b0045","unstructured":"Regulations USCoF. 21 CFR Part 600.80 Postmarketing reporting of adverse experiences. 21: Federal Register; 2014."},{"key":"10.1016\/j.vaccine.2016.07.019_b0050","unstructured":"VAERS Table of Reportable Events Following Vaccination."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2016.07.019_b0055","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1542\/peds.2010-1722L","article-title":"Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program","volume":"127","author":"Salmon","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.07.019_b0060","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.2105\/AJPH.92.12.1900","article-title":"The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance","volume":"92","author":"Rubertone","year":"2002","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2016.07.019_b0065","unstructured":"Centers for Disease Control and Prevention. Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage \u2013 United States, October 2009-January 2010. MMWR Morbidity and mortality weekly report, vol. 59, 2010, pp. 363\u2013368."},{"key":"10.1016\/j.vaccine.2016.07.019_b0070","unstructured":"Centers for Disease Control and Prevention. Interim results: influenza A (H1N1) 2009 monovalent and seasonal influenza vaccination coverage among health-care personnel \u2013 United States, August 2009-January 2010. MMWR Morbidity and mortality weekly report, vol. 59, 2010, pp. 357\u2013362."},{"key":"10.1016\/j.vaccine.2016.07.019_b0075","unstructured":"Centers for Disease Control and Prevention. Interim results: influenza A (H1N1) 2009 monovalent vaccination coverage --- United States, October-December 2009. MMWR Morbidity and mortality weekly report, vol. 59, 2010, pp. 44\u201348."},{"key":"10.1016\/j.vaccine.2016.07.019_b0080","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/sim.5333","article-title":"Combining estimates from two surveys: an example from monitoring 2009 influenza A (H1N1) pandemic vaccination","volume":"31","author":"Furlow-Parmley","year":"2012","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2016.07.019_b0085","unstructured":"Brighton Collaboration Definitions & Guidelines; 2008. <https:\/\/brightoncollaboration.org\/public\/what-we-do\/setting-standards\/case-definitions\/available-definitions.html>; cited 2015."},{"key":"10.1016\/j.vaccine.2016.07.019_b0090","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.07.019_b0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barr\u00e9 syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.07.019_b0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archneur.1982.00510130023004","article-title":"Guillain-Barre syndrome in the US Army","volume":"39","author":"Johnson","year":"1982","journal-title":"Arch Neurol"},{"key":"10.1016\/j.vaccine.2016.07.019_b0105","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/oxfordjournals.aje.a115974","article-title":"Guillain-Barre syndrome and influenza vaccination in the US Army, 1980\u20131988","volume":"133","author":"Roscelli","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.07.019_b0110","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/aje\/kws195","article-title":"Risk of confirmed Guillain-Barr\u00e9 syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009\u20132010","volume":"175","author":"Greene","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.07.019_b0115","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/pds.3220","article-title":"The risk of Guillain-Barr\u00e9 syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009\u20132010 seasonal influenza vaccines: results from self-controlled analyses","volume":"21","author":"Tokars","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2016.07.019_b0120","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/aje\/kws196","article-title":"Guillain-Barr\u00e9 syndrome during the 2009\u20132010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans","volume":"175","author":"Wise","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.07.019_b0125","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2105\/AJPH.2011.300510","article-title":"Surveillance for Guillain-Barr\u00e9 syndrome after influenza vaccination among the Medicare population, 2009\u20132010","volume":"102","author":"Burwen","year":"2012","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2016.07.019_b0130","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","article-title":"Association between Guillain-Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis","volume":"381","author":"Salmon","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.07.019_b0135","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annepidem.2007.03.018","article-title":"Concurrent vaccinations and U.S. military hospitalizations","volume":"17","author":"Payne","year":"2007","journal-title":"Ann Epidemiol."},{"key":"10.1016\/j.vaccine.2016.07.019_b0140","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1016\/j.vaccine.2014.09.018","article-title":"Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013","volume":"32","author":"Haber","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.07.019_b0145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1756-0500-2-171","article-title":"The epidemiology of Guillain-Barr\u00e9 Syndrome in U.S. military personnel: a case-control study","volume":"2","author":"Nelson","year":"2009","journal-title":"BMC Research Notes"},{"key":"10.1016\/j.vaccine.2016.07.019_b0150","first-page":"355","article-title":"The Guillain-Barr\u00e9 Syndrome; pathogenesis and treatment","volume":"152","author":"Van Der Meche","year":"1996","journal-title":"Rev Neurol Paris"},{"key":"10.1016\/j.vaccine.2016.07.019_b0155","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/165.3.557","article-title":"Treatment of traveler\u2019s diarrhea with ciprofloxacin and loperamide","volume":"165","author":"Petruccelli","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.07.019_b0160","doi-asserted-by":"crossref","first-page":"582","DOI":"10.7326\/0003-4819-118-8-199304150-00002","article-title":"Ciprofloxacin and loperamide in the treatment of bacillary dysentery","volume":"118","author":"Murphy","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2016.07.019_b0165","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/jcm.31.12.3351-3352.1993","article-title":"Diarrhea in U.S. troops deployed to Thailand","volume":"31","author":"Echeverria","year":"1993","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2016.07.019_b0170","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/pds.1349","article-title":"Comparison of military and civilian reporting rates for smallpox vaccine adverse events","volume":"16","author":"McMahon","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2016.07.019_b0175","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/pds.936","article-title":"Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"13","author":"Sever","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2016.07.019_b0180","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/pds.1359","article-title":"Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967\u20131972 study and review of the 1955\u20132005 medical literature","volume":"16","author":"McNeil","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2016.07.019_b0185","unstructured":"Centers for Disease Control and Prevention. National Early Season Flu Vaccination Coverage, United States, November 2014. <http:\/\/www.cdc.gov\/flu\/fluvaxview\/nifs-estimates-nov2014.htm>. 2016."},{"key":"10.1016\/j.vaccine.2016.07.019_b0190","unstructured":"Centers for Disease Control and Prevention. Fact Sheet: Guillain-Barr\u00e9 Syndrome (GBS), 2009. <http:\/\/www.cdc.gov\/h1n1flu\/vaccination\/factsheet_gbs.htm>."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T14:31:57Z","timestamp":1656858717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16305928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":38,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0264410X16305928"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.07.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009\u20132010 season in the active component U.S. military and civilians aged 17\u201344years reported to the Vaccine Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}